Loading
Exact Sciences' development study of the methylation and protein classifier behind Cancerguard: it found about half of cancers overall but about one in seven stage I cancers.
Gainullin and colleagues assessed a methylation and protein (MP) classifier in a prospectively collected multi-centre case-control set of 6,352 samples (1,438 cancer, 4,914 non-cancer) across 21 tumour organ types, split between training and test sets. At 98.5% specificity, overall sensitivity was 50.9%, with 15.4% at stage I, 26.1% at stages I and II combined, 38.0% at stage II, 67.8% at stage III and 85.5% at stage IV. Excluding breast and prostate cancers, overall sensitivity was 56.8% and stage I sensitivity 17.2%. A somatic mutation reflex for borderline samples was explored.
It is the only peer-reviewed stage-by-stage figure for the Cancerguard approach, and it describes a development classifier at 98.5% specificity, not the launched test, which Exact Sciences says runs at 97.4% specificity.
Shares Cancerguard, Exact Sciences (Abbott), Multi-cancer early detection (MCED).
Shares Cancerguard, Exact Sciences (Abbott), Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Cancerguard, Exact Sciences (Abbott), Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Exact Sciences (Abbott), Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/